Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SDGR

Schrodinger Inc

Oct 22 • 04:00PM ET

20.79

-0.08 -0.38 %

Healthcare • Health Information Services • USA • NASD

Peers: REGN GILD BIIB VRTX BMRN NBIX INCY EXEL SAGE IONS

| Held by: IJR ARKG VTI VB IWM VBK VXF IWO SPSM SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.48	Insider Own	14.87%	Shs Outstand	64.42M	Perf Week	0.87%
Market Cap	1.53B	Forward P/E	-	EPS next Y	-1.87	Insider Trans	-0.01%	Shs Float	62.66M	Perf Month	9.08%
Enterprise Value	1.18B	PEG	-	EPS next Q	-0.72	Inst Own	97.77%	Short Float	15.49%	Perf Quarter	-7.56%
Income	-181.33M	P/S	6.43	EPS this Y	9.30%	Inst Trans	6.02%	Short Ratio	8.12	Perf Half Y	-18.34%
Sales	237.92M	P/B	4.46	EPS next Y	19.59%	ROA	-26.34%	Short Interest	9.71M	Perf YTD	7.78%
Book/sh	4.66	P/C	3.31	EPS next 5Y	16.58%	ROE	-44.40%	52W High	28.47 -26.98%	Perf Year	16.80%
Cash/sh	6.28	P/FCF	62.79	EPS past 3/5Y	-21.88% -45.98%	ROIC	-41.18%	52W Low	16.60 25.23%	Perf 3Y	-7.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.59% 19.39%	Gross Margin	57.93%	Volatility	6.81% 5.67%	Perf 5Y	-62.79%
Dividend TTM	-	EV/Sales	4.97	EPS Y/Y TTM	10.96%	Oper. Margin	-81.09%	ATR (14)	1.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.30	Sales Y/Y TTM	18.59%	Profit Margin	-76.22%	RSI (14)	53.35	Recom	1.70
Dividend Gr. 3/5Y	- -	Current Ratio	3.30	EPS Q/Q	20.89%	SMA20	2.27%	Beta	1.77	Target Price	27.00
Payout	-	Debt/Eq	0.33	Sales Q/Q	15.69%	SMA50	5.36%	Rel Volume	1.05	Prev Close	20.87
Employees	891	LT Debt/Eq	0.28	Earnings	Nov 05 AMC	SMA200	-4.15%	Avg Volume	1.20M	Price	20.79
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.16% 5.21%	Trades		Volume	1,256,765	Change	-0.38%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Initiated	Goldman	Neutral	$19
Aug-15-25	Downgrade	Citigroup	Buy → Neutral	$20
Aug-14-25	Initiated	Barclays	Overweight	$25
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$28
Jul-02-24	Initiated	Leerink Partners	Outperform	$29
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$38
May-05-23	Resumed	Piper Sandler	Overweight	$60
Dec-19-22	Initiated	Goldman	Neutral	$23
Mar-01-22	Initiated	Citigroup	Buy	$55
Nov-19-21	Initiated	Piper Sandler	Overweight	$87
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$82 → $49
Nov-11-21	Downgrade	BofA Securities	Buy → Neutral	$80 → $52
Oct-13-21	Initiated	Berenberg	Buy	$91
Sep-01-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$82
May-25-21	Initiated	Craig Hallum	Buy	$85
Nov-23-20	Upgrade	BofA Securities	Neutral → Buy	$74
Oct-12-20	Upgrade	Jefferies	Hold → Buy
Mar-02-20	Initiated	Morgan Stanley	Equal-Weight	$43
Mar-02-20	Initiated	Jefferies	Hold	$42
Mar-02-20	Initiated	BMO Capital Markets	Outperform	$65

Show Previous Ratings

Today 08:30AM	Schrodinger to Announce Third Quarter 2025 Financial Results on November 5 (Business Wire)
Oct-21-25 07:05AM	Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength? (Zacks) -5.05%
Oct-15-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.07%
Sep-18-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-09-25 09:55AM	Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect? (Zacks)
08:30AM	Loading…
Aug-27-25 08:30AM	Schrodinger to Present at Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-15-25 04:30PM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-14-25 07:00AM	Schrödinger Announces Discontinuation of SGR-2921 Program (Business Wire)
07:00AM	Schrodinger Announces Discontinuation of SGR-2921 Program (Business Wire)
Aug-06-25 06:30PM	Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 06:05PM	Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates (Zacks)
09:52AM	Earnings To Watch: Schrodinger Inc (SDGR) Reports Q2 2025 Result (GuruFocus.com)
Aug-01-25 12:08PM	Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition? (Zacks)
08:30AM	Loading…
Jul-25-25 08:30AM	Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
08:30AM	Schrodinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-24-25 10:00AM	Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-23-25 10:02AM	Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? (Zacks)
10:00AM	Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 08:00AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-17-25 08:00AM	Ajax Therapeutics and Schrdinger Expand Research Collaboration to Include Additional JAK Target (Business Wire)
Jul-16-25 09:58AM	Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage on Schrodinger (SDGR) Stock (Insider Monkey)
Jul-07-25 10:23AM	Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? (Zacks)
Jul-04-25 09:45AM	Meta upgraded, PNC Financial downgraded: Wall Streets top analyst calls (TipRanks)
Jul-03-25 09:41AM	Meta upgraded, PNC Financial downgraded: Wall Street's top analyst calls (The Fly)
08:35AM	MS initiates coverage on AI Biotechs, flags key pipeline catalysts (Investing.com)
Jul-02-25 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
10:05AM	Loading…
10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jun-27-25 08:00AM	Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia (Business Wire)
08:00AM	Schrodinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenstrom Macroglobulinemia (Business Wire)
Jun-17-25 08:30AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-12-25 07:00AM	Schrdinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress (Business Wire) -14.44%
May-29-25 05:00PM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (Business Wire)
05:00PM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (Business Wire)
08:00AM	Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing (Business Wire)
08:00AM	Schrodinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing (Business Wire)
May-27-25 10:00AM	RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? (Zacks)
May-23-25 08:30AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-22-25 08:30AM	Schrödinger to Present at Jefferies Global Healthcare Conference (Business Wire)
08:30AM	Schrodinger to Present at Jefferies Global Healthcare Conference (Business Wire)
May-21-25 04:26AM	Leadership Transition at Schrodinger: Richie Jain Named CFO (Insider Monkey)
May-20-25 07:00AM	Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (BioPharma Dive) -8.62%
06:30AM	Schrödinger Announces CFO Appointment (Business Wire)
06:30AM	Schrodinger Announces CFO Appointment (Business Wire)
May-14-25 09:30AM	Schrdinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma (Business Wire)
May-08-25 07:42AM	Q1 2025 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com)
May-07-25 06:40PM	Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Schrodinger projects strong 2025 revenue growth with $45M-$50M in drug discovery (Seeking Alpha)
05:59PM	Schrodinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:05PM	Schrdinger Reports Strong First Quarter 2025 Financial Results (Business Wire)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.31%
May-05-25 12:35PM	AI Healthcare Boom Gains Speed as Regulators and Innovators Align (PR Newswire)
08:30AM	Schrdinger to Present at BofA Securities 2025 Healthcare Conference (Business Wire)
May-02-25 08:10AM	Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-28-25 08:00AM	Schrdinger Presents New Preclinical Data at AACR Annual Meeting (Business Wire)
Apr-23-25 10:27AM	Schrodinger, Inc. (SDGR): Among Top Stocks in Bill Gates' Portfolio with Huge Upside Potential (Insider Monkey)
08:30AM	Schrdinger to Announce First Quarter 2025 Financial Results on May 7 (Business Wire)
06:01AM	2 Strong Buy Stocks That Are Crashing the Market in April (TipRanks)
Apr-21-25 08:00AM	3 Momentum Stocks That Could Soar Post-Market Volatility (MarketBeat)
Apr-18-25 08:30AM	Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-14-25 08:00AM	Schrdingers Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs (Business Wire) +8.37%
04:18AM	Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? (Zacks)
Apr-12-25 10:26AM	Schrodinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) (Seeking Alpha)
Apr-11-25 01:15PM	Buy Certara After The FDA Announcement (Seeking Alpha) +27.42%
Mar-25-25 05:12PM	Schrdinger to Present Preclinical Data at AACR Annual Meeting (Business Wire) -5.71%
Mar-18-25 08:30AM	Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-10-25 08:30AM	Schrdinger Expands Board of Directors with Appointment of Bridget van Kralingen (Business Wire) -5.04%
Feb-27-25 10:54AM	Q4 2024 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Schrodinger Inc (SDGR) Q4 2024 Earnings Call Highlights: Strong Software Growth Amidst Revenue ... (GuruFocus.com)
Feb-26-25 06:00PM	Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results (Business Wire)
Feb-25-25 10:30AM	Schrodinger Inc (SDGR) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 08:30AM	Schrodinger to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.73%
Feb-18-25 12:50PM	Why Xpeng (XPEV) and Schrodinger (SDGR) Are Advancing Today (Insider Monkey)
Feb-14-25 03:47PM	Schrodinger Stock Scores IBD Rating Upgrade (Investor's Business Daily)
Feb-12-25 08:30AM	Schrdinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26 (Business Wire)
Jan-29-25 01:45PM	Schrödinger (SDGR): Revolutionizing Biopharma with Quantum Mechanics and AI (Insider Monkey)
Jan-24-25 12:32PM	Schrödinger, Inc. (SDGR): Quantum Mechanics Meets AI in Biopharma, Backed by Hunterbrooks Key AI Winner Endorsement (Insider Monkey)
Jan-23-25 03:36PM	Why Schrödinger, Inc. (SDGR) Is Skyrocketing Now (Insider Monkey)
03:43AM	Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Jan-22-25 11:29AM	Why Drug Developers That Utilize AI, Including SDGR and RXRX, Are Jumping (Insider Monkey) +14.11%
08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 07:00AM	Schrodinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities (Business Wire)
Dec-17-24 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-20-24 08:30AM	Schrdinger to Present at Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-19-24 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 08:30AM	Schrdinger Broadens and Accelerates Predictive Toxicology Initiative (Business Wire)
Nov-13-24 06:56AM	Schrodinger announces expanded license agreement with Novartis (TipRanks)
02:06AM	Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
12:54AM	Q3 2024 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 11:06AM	Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details (Benzinga) +13.87%
08:05AM	Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)

Schrodinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dugan Margaret	Chief Medical Officer	Oct 16 '25	Sale	21.07	1,395	29,387	24,574	Oct 17 04:28 PM
Dugan Margaret	Officer	Oct 16 '25	Proposed Sale	21.07	1,395	29,387		Oct 16 03:16 PM
Akinsanya Karen	President of R&D, Therapeutics	Apr 14 '25	Option Exercise	3.16	16,723	52,845	32,348	Apr 15 04:31 PM
Akinsanya Karen	President of R&D, Therapeutics	Apr 14 '25	Sale	25.09	16,723	419,570	15,625	Apr 15 04:31 PM
Karen Akinsanya	Officer	Apr 14 '25	Proposed Sale	24.49	16,723	409,546		Apr 14 04:20 PM
Herman Jenny	SVP & Controller	Mar 06 '25	Sale	21.11	666	14,059	27,349	Mar 07 04:14 PM
Herman Jenny	Officer	Mar 06 '25	Proposed Sale	21.11	666	14,056		Mar 06 04:16 PM
Porges Geoffrey Craig	EVP & CFO	Mar 03 '25	Sale	21.76	5,491	119,484	27,544	Mar 04 05:29 PM
Porges Geoffrey Craig	Officer	Mar 03 '25	Proposed Sale	21.76	5,491	119,481		Mar 03 03:30 PM
Tran Yvonne	EVP, CLO & CPO	Feb 18 '25	Option Exercise	4.34	3,902	16,935	15,037	Feb 19 04:09 PM
Tran Yvonne	EVP, CLO & CPO	Feb 18 '25	Sale	28.00	3,902	109,256	11,135	Feb 19 04:09 PM
YVONNE TRAN	Officer	Feb 18 '25	Proposed Sale	24.85	3,902	96,965		Feb 18 04:27 PM
Abel Robert Lorne	See Remarks	Feb 10 '25	Sale	25.99	1,225	31,838	8,115	Feb 12 04:09 PM
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Feb 11 '25	Sale	24.43	985	24,064	41,076	Feb 12 04:08 PM
Herman Jenny	SVP & Controller	Feb 11 '25	Sale	24.43	859	20,985	18,215	Feb 12 04:07 PM
Tran Yvonne	EVP, CLO & CPO	Feb 11 '25	Sale	24.43	828	20,228	11,135	Feb 12 04:07 PM
Lorton Kenneth Patrick	Officer	Feb 11 '25	Proposed Sale	24.43	985	24,064		Feb 11 06:34 PM
Herman Jenny	Officer	Feb 11 '25	Proposed Sale	24.43	859	20,986		Feb 11 04:15 PM
Tran Yvonne	Officer	Feb 11 '25	Proposed Sale	24.43	828	20,228		Feb 11 04:13 PM
Abel Robert Lorne	Officer	Feb 10 '25	Proposed Sale	25.18	2,636	66,374		Feb 10 05:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SDGR

Schrodinger Inc

Upgrade your FINVIZ experience